Opinion: To Accelerate Rare Disease Progress, Take a Sandbox Approach

The opinion piece in BioSpace, “To Accelerate Rare Disease Progress, Take a Sandbox Approach” argues that traditional rare disease drug development is too slow and rigid, leaving approximately 95% of rare conditions without FDA-approved treatments. The authors propose adopting a “sandbox” model—a flexible, collaborative regulatory environment where developers, regulators, patients, and experts can iteratively test innovative methods, trial designs, and data strategies. By tailoring sandbox frameworks to disease types and treatment modalities, fostering ongoing dialogue with regulators, and integrating robust data-driven modeling, this approach could streamline clinical programs, encourage adaptive clinical trial designs, and ultimately bring effective therapies to rare disease patients sooner.